Follicular lymphoma (FL) is a systemic neoplasm of the lymphoid tissue displaying germinal
centre (GC) B cell differentiation. FL represents~ 5% of all haematological neoplasms and …

With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …

The fifth edition of the World Health Organization Classification of Haematolymphoid
Tumours (WHO‐HAEM5) is the product of an evidence‐based evolution of the revised fourth …

Diagnosis should be based on a surgical specimen/excisional lymph node (LN) biopsy.
Core biopsies should only be carried out in patients without easily accessible LNs (eg …

Observational studies and stand-alone trials indicate that patients with follicular lymphoma
(FL) who experience disease progression within 24 months of front-line …

Despite widespread use of bendamustine and rituximab (BR) as frontline therapy for
advanced-stage follicular lymphoma (FL), little is known about the risk of early progression …

Follicular lymphoma (FL) is a B-cell malignancy with a complex tumor microenvironment that
is rich in nonmalignant immune cells. We applied single-cell RNA sequencing to …

Tumor heterogeneity complicates biomarker development and fosters drug resistance in
solid malignancies. In lymphoma, our knowledge of site-to-site heterogeneity and its clinical …

PURPOSE Understanding the immunobiology of the 15% to 30% of patients with follicular
lymphoma (FL) who experience progression of disease within 24 months (POD24) remains …

We evaluated early disease progression and its impact on overall survival (OS) in previously
untreated follicular lymphoma patients in GALLIUM (clinicaltrials. gov identifier: 01332968) …